55 PARK LANE, LONDON, X0
Market cap: $78.6M (2/09/2026)
Price: $2.09
Enters into Sales Agreement with Leerink Partners for At the Market Offering Program
Strengthens World Class Leadership Team with Appointment of Flavio Mantelli, MD, PhD as Chief Medical Officer
Issues Interim Results for the Six Months Ended September 30, 2025
Announces Acceptance of Urcosimod Phase 2 Study Results for Presentation at Prestigious ASCRS Annual Meeting
Announces Successful Type C Meeting with the FDA
FDA Approves Compassionate Use of Urcosimod (0.05%) for the Treatment of Neuropathic Corneal Pain
Appoints Industry Veteran Robert J. Dempsey as Chief Executive Officer
Announces Opening Bell Ceremony at Nasdaq MarketSite
Amended Annual and Transition Report of Foreign Private Issuers
Annual and Transition Report of Foreign Private Issuers
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis
No filings found
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Amended Statement of Changes in Beneficial Ownership
NT 20-F
Free Writing Prospectus
Correspondence